

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/192283 A1

(51) International Patent Classification:

A61B 17/00 (2006.01) A61M 31/00 (2006.01)
A61F 2/02 (2006.01)

(21) International Application Number:

PCT/US2022/019379

(22) International Filing Date:

08 March 2022 (08.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/158,017	08 March 2021 (08.03.2021)	US
63/181,594	29 April 2021 (29.04.2021)	US
63/241,224	07 September 2021 (07.09.2021)	US
63/251,159	01 October 2021 (01.10.2021)	US
63/271,972	26 October 2021 (26.10.2021)	US

(71) Applicant: **LYRA THERAPEUTICS, INC.** [US/US];
480 Arsenal Street, Watertown, MA 02472 (US).

(72) Inventors: **CERVIN, Anders**; 480 Arsenal Way, Watertown, MA 02472 (US). **RIMMER, Joanne**; 480 Arsenal Way, Watertown, MA 02472 (US). **WROBEL, Agnieszka**;

480 Arsenal Way, Watertown, MA 02472 (US). **ABELAK, Yogen**; 480 Arsenal Way, Watertown, MA 02472 (US). **BRAYTON, Lindsay**; 480 Arsenal Way, Watertown, MA 02472 (US). **KUANG, Yina**; 480 Arsenal Way, Watertown, MA 02472 (US).


(74) Agent: **CARROL, Peter, G.** et al.; MEDLEN & CARROLL, LLP, 1440 Broadway, Suite 1010, Oakland, California 94612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: IMPLANTABLE CORTICOSTEROID MATRIX FOR SINUS CONDITION

Fig. 1



(57) Abstract: The present invention relates to materials, devices, kits and methods for use in treatment of patients having a sinus condition, including those with (or at risk of having) severe chronic rhinosinusitis (CRS) symptoms. More specifically, in some embodiments, a device is a long-acting corticosteroid matrix.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))